CG Oncology, Inc. CGON
72.61 USD -0.03 (-0.04%)
At closeNov 11, 2026, 4:00 PM EST
72.61 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
72.49 Day range 75.19
37.01 52-week range 80.97
- YTD
- +74.88%
- 1 year
- +86.95%
News
benzinga.com Guggenheim Maintains Buy on CG Oncology, Lowers Price Target to $89 Guggenheim analyst Michael Schmitz maintains CG Oncology (NASDAQ:CGON) with a Buy and lowers the price target from $90 to $89.
defenseworld.net CG Oncology, Inc. $CGON Stock: Candriam S.C.A. Cuts Position Candriam S.C.A. lessened its position in CG Oncology, Inc. (NASDAQ: CGON) by 20.0% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 375,362 shares of the…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…
zacks.com CG Oncology, Inc. (CGON) Reports Q3 Loss, Beats Revenue Estimates CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.57 per share a year ago.- benzinga.com CG Oncology Q3 EPS $(0.64) Beats $(0.82) Estimate, Sales $1.604M Beat $643.584K Estimate CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.82) by 21.95 percent. This is a 12.28 percent decrease over losses of $(0.57)…
globenewswire.com CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the third quarter ended September 30, 2026, and provided business updates.
seekingalpha.com CG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy CG Oncology is well-positioned to enter a de-risked NMIBC market with cretostimogene, offering a clean tolerability profile and randomized Phase 3 data. CGON's $1B+ cash position funds operations…
defenseworld.net CG Oncology (NASDAQ:CGON) Director Leonard Post Sells 1,000 Shares of Stock CG Oncology, Inc. (NASDAQ: CGON - Get Free Report) Director Leonard Post sold 1,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of…
globenewswire.com CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical…
gurufocus.com Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC
prnewswire.com Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached…
defenseworld.net Insider Selling: CG Oncology (NASDAQ:CGON) Director Sells $72,980.00 in Stock CG Oncology, Inc. (NASDAQ: CGON - Get Free Report) Director Leonard Post sold 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an…
seekingalpha.com CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
defenseworld.net 23,000 Shares in CG Oncology, Inc. $CGON Purchased by Jupiter Topco LLC Jupiter Topco LLC purchased a new stake in shares of CG Oncology, Inc. (NASDAQ: CGON) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission…
schaeffersresearch.com 15 Stocks to Watch With Short Squeeze Potential Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.
globenewswire.com CG Oncology to Present at Upcoming Investor Conferences in September DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
prnewswire.com Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached…
seekingalpha.com CG Oncology: Circling Back After Huge Rally CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy and best-in-class safety versus competitors. Cret achieved a 75% anytime CR, 46% 12-month CR, and…
defenseworld.net CG Oncology, Inc. $CGON Shares Bought by California State Teachers Retirement System California State Teachers Retirement System increased its stake in CG Oncology, Inc. (NASDAQ: CGON) by 23.6% during the undefined quarter, according to the company in its most recent 13F filing with…
benzinga.com RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79 RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and lowers the price target from $81 to $79.
benzinga.com Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85 Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $82 to $85.
benzinga.com Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85 Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $82 to $85.
zacks.com CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.54 per share a year ago.- benzinga.com CG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K Estimate CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.67) by 34.33 percent. This is a 66.67 percent decrease over losses of…
globenewswire.com CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the second quarter ended June 30, 2026, and provided business updates.
globenewswire.com Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached…
globenewswire.com CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder…- benzinga.com ANI Pharmaceuticals Plans To Appeal Judge Sheldon K. Rennie's Decision To Deny ANI's Post-Trial Motions For New Trial, Judgement; Co. Seeks To Recover Assets' Value Sold to CG Oncology Under 2010 Deal ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI’s post-trial motions for a new trial and judgment as a matter…
- benzinga.com HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $100 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $100 price target.
- benzinga.com CG Oncology Reports First Results From CORE‑008 Cohort CX Phase 2 Trial - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively- High-Grade - EFS in the overall…
benzinga.com Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $82 Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $77 to $82.- benzinga.com JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $96 JP Morgan analyst Brian Cheng maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $91 to $96.
benzinga.com CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings CG Oncology (NASDAQ:CGON) reported mixed results for Q1, with losses of 71 cents per share and sales of $1.083 million. Analysts have adjusted price targets.
benzinga.com RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $81 RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $79 to $81.
benzinga.com Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $77 Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $75 to $77.
benzinga.com Wedbush Maintains Outperform on CG Oncology, Raises Price Target to $80 Wedbush analyst Yun Zhong maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $77 to $80.
benzinga.com CG Oncology Q1 EPS $(0.71) Misses $(0.57) Estimate, Sales $1.083M Beat $493.182K Estimate CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.57) by 24.56 percent. This is a 57.78 percent decrease over losses of…
benzinga.com RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $79 RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $73 to $79.- benzinga.com HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $100 HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $80 to $100.
benzinga.com What Analysts Are Saying About CG Oncology Stock - benzinga.com HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $80 HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $75 to $80.
benzinga.com CG Oncology Q4 Earnings Report: What Investors Need to Know - benzinga.com CG Oncology Q4 EPS $(0.51) Beats $(0.59) Estimate, Sales $2.322M Beat $1.641M Estimate CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.59) by 13.56 percent. This is a 10.87 percent decrease over losses of $(0.46)…
benzinga.com Expert Outlook: CG Oncology Through The Eyes Of 7 Analysts - benzinga.com Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $75 Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $66 to $75.
- benzinga.com What Analysts Are Saying About CG Oncology Stock
- benzinga.com RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $73 RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $61 to $73.
- benzinga.com Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $70 Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $55 to $70.
- benzinga.com Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $66 Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $62 to $66.